T35395 |
Camrelizumab (anti-PD-1)
|
|
98%
|
|
|
T36900 |
PD-1/PD-L1-IN-NP19
|
2377916-66-8
|
98%
|
|
PD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenviron...
|
T35394 |
Sintilimab (anti-PD-1)
|
|
98%
|
|
|
T12377 |
PD-1-IN-17
|
1673560-66-1
|
98%
|
|
PD-1-IN-17 is an inhibitor of programmed cell death-1 (PD-1). PD-1-IN-17 inhibits 92% splenocyte proliferation at 100 nM.
|
T35396 |
Spartalizumab (anti-PD-1)
|
|
98%
|
|
|
T9616 |
PD-1/PD-L1-IN-10
|
2487550-41-2
|
98%
|
|
PD-1/PD-L1-IN-10 is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy.
|
T12379 |
PD-1-IN-22
|
2349372-98-9
|
98%
|
|
PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor(IC50 of 92.3 nM).
|
TP1076L |
AUNP-12 acetate
|
|
98%
|
|
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in addition t...
|
T9908 |
Pembrolizumab
|
1374853-91-4
|
|
|
Pembrolizumab is a humanized monoclonal antibody inhibiting the PD-1 receptor and the first in the class of agents called the HER2 dimerization inhibitors that i...
|
T9903 |
Avelumab
|
1537032-82-8
|
|
|
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody. Avelumab shows potential antibody-dependent cell-mediated cytotoxicity.
|
T9907 |
Nivolumab
|
946414-94-4
|
|
|
Nivolumab anti-PD-1) is a genetically engineered fully human immunoglobulin Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell ...
|
T9902 |
Atezolizumab
|
1380723-44-3
|
|
|
Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD...
|
T9359 |
PDL-1 cpd 10
|
T9359
|
97.68%
|
|
PDL-1 cpd 10 is a novel small molecule PD-L1 inhititor.
|
T8470 |
BMS-1001
|
2113650-03-4
|
98.89%
|
|
BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction(IC50 : 2.25 nM, in a homogenous time-resolved fluorescence binding assay).
|
T26859 |
BMS-8
|
1675201-90-7
|
99.06%
|
|
BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction.
|
T5697 |
BMS-1166
|
1818314-88-3
|
99.14%
|
|
BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor.
|
T0844 |
Sulfamethoxypyridazine
|
80-35-3
|
99.3%
|
|
Sulfamethoxypyridazine is a sulfanilamide antibacterial agent.
|
T6S0071 |
Fraxinellone
|
28808-62-0
|
99.35%
|
|
1. Fraxinellone significantly reduced weight loss and diarrhea in mice and alleviated the macroscopic and microscopic signs of the disease. 2. Fraxinellone exhib...
|
T9651 |
PD-1/PD-L1-IN-9
|
2628506-54-5
|
99.37%
|
|
PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, IC50 = 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells...
|
T4696 |
BMS202 hydrochloride (1675203-84-5(free base))
|
T4696
|
99.47%
|
|
PD-1/PD-L1 inhibitor 2 is a small-molecule PD-1/PD-L1 interaction inhibitor (IC50: 18 nM). Biophysical studies demonstrate that BMS202 binds directly to PD-L1. B...
|